恩西地平治疗突变型IDH2急性髓系白血病患者的分子缓解与缓解模式
约8%至19%的急性髓系白血病(AML)患者携带异柠檬酸脱氢酶-2(IDH2)突变。这项首次人体1/2期研究评估恩西地平50至650 mg/d连续28天周期给药,345例患者中214例(62%)复发或难治性AML接受100 mg/d,完全缓解率19.6%,总缓解率38.8%,中位总生存8.8个月。
要点
- 214例复发或难治性AML患者接受恩西地平100 mg/d,完全缓解率19.6%,总缓解率38.8%。
- 中位总生存8.8个月(95%CI 7.7-9.6),IDH2-R140与R172突变患者缓解和生存相当。
- 43.1%红细胞输注依赖者和40.2%血小板输注依赖者 achieve 输血独立。
核心结论
- 恩西地平耐受良好,在既往治疗失败的AML患者中诱导分子缓解和血液学缓解。
研究设计与样本
- 首次人体1/2期研究,评估恩西地平50至650 mg/d连续28天周期给药,用于突变型IDH2血液系统恶性肿瘤患者。
- 345例患者中214例(62%)复发或难治性AML接受恩西地平100 mg/d,中位年龄68岁。
- 研究注册号NCT01915498。
主要发现
- 42例(19.6%)达到完全缓解,19例(10.3%)接受异基因骨髓移植,总缓解率38.8%(95%CI 32.2-45.7)。
- 中位总生存8.8个月(95%CI 7.7-9.6)。
- IDH2-R140或IDH2-R172突变患者缓解和生存相当。
- 研究入组时复发患者缓解率37.7%,对强化治疗难治者37.5%,对非强化治疗难治者43.2%。
- 66例(43.1%)红细胞输注依赖和53例(40.2%)血小板输注依赖患者达到输血独立。
关键数值与推荐
- IDH2-R172患者中2-HG降低幅度与完全缓解相关。
- 突变型IDH2克隆清除与达到完全缓解相关。
- 全部345例患者中,最常见3或4级治疗相关不良事件为高胆红素血症(10%)、血小板减少(7%)和IDH分化综合征(6%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Approximately 8% to 19% of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur at active site arginine residues R140 and R172. IDH2 mutations produce an oncometabolite, 2-hydroxyglutarate (2-HG), which leads to DNA and histone hypermethylation and impaired hematopoietic differentiation. Enasidenib is an oral inhibitor of mutant-IDH2 proteins. This first-in-human phase 1/2 study evaluated enasidenib doses of 50 to 650 mg/d, administered in continuous 28-day cycles, in patients with mutant-IDH2 hematologic malignancies. Overall, 214 of 345 patients (62%) with relapsed or refractory (R/R) AML received enasidenib, 100 mg/d. Median age was 68 years. Forty-two patients (19.6%) attained complete remission (CR), 19 patients (10.3%) proceeded to an allogeneic bone marrow transplant, and the overall response rate was 38.8% (95% confidence interval [CI], 32.2-45.7). Median overall survival was 8.8 months (95% CI, 7.7-9.6). Response and survival were comparable among patients with IDH2-R140 or IDH2-R172 mutations. Response rates were similar among patients who, at study entry, were in relapse (37.7%) or were refractory to intensive (37.5%) or nonintensive (43.2%) therapies. Sixty-six (43.1%) red blood cell transfusion-dependent and 53 (40.2%) platelet transfusion-dependent patients achieved transfusion independence. The magnitude of 2-HG reduction on study was associated with CR in IDH2-R172 patients. Clearance of mutant-IDH2 clones was also associated with achievement of CR. Among all 345 patients, the most common grade 3 or 4 treatment-related adverse events were hyperbilirubinemia (10%), thrombocytopenia (7%), and IDH differentiation syndrome (6%). Enasidenib was well tolerated and induced molecular remissions and hematologic responses in patients with AML for whom prior treatments had failed. The study is registered at www.clinicaltrials.gov as #NCT01915498.
引用
- Stein EM, DiNardo CD, Fathi AT, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2018. PMID: 30510081. doi:10.1182/blood-2018-08-869008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。